Loading…
Loading…
Arizona State Retirement System grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 5.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 38,025 shares of the biopharmaceutical company's stock after acquiring an additional 2,126 shares during the period. Arizona
Concurrent Investment Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 695.9% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,521 shares of the biopharmaceutical company's stock after purchasing an additional 6,576 shares during the
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 8:45 AM ET in Everett, Massachusetts Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 10:00 AM ET in New York City A live audio webcast of each pre.
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty-four research firms that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong
[url="]Alnylam Pharmaceuticals, Inc[/url]. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data ex.